trial summary · NCT07227103
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Treatment Resistant Depression, sponsored by NeuroRx, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes. This study will compare Rapid Robotically-guided Transcranial Magnetic Stimulation (RRTMS) combined with an investigational neuroplasticity-inducing medication (NRX-101) to the effects of (1) sham TMS treatment and (2) placebo in achieving clinical response and remission from depression in patients with Treatment Resistant Depression. DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When a one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week. This trial will compare response and remission at six weeks following neuronavigated robotic-enabled Transcranial Magnetic Stimulation + NRX-101 (D-cycloserine/lurasidone) vs. TMS+placebo.
Source record: https://clinicaltrials.gov/study/NCT07227103
Facts
| registry id | NCT07227103 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2/PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Treatment Resistant Depression |
| sponsor | NeuroRx, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 240 |
| start date | 2026-12-01 |
| primary completion | 2027-12-31 |
| completion | 2028-06-30 |
| results posted | not reported |
Conditions
- Treatment Resistant Depression
- Treatment Resistant Depression (TRD)
Interventions
- Neuronavigated robotic-enabled TMS
- NRX-101
- Sham TMS
- Oral Placebo
Countries
- United States
Intervention types: DEVICE, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.